BridgeBio Pharma, Inc.
Close on Oct 19, 2026
- Market cap
- $13.30B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Oct 28, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 10, 2026 | After market close | $243.70M | $-0.78 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | After market close | $194.50M | $-0.84 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 24, 2026 | After market close | $154.20M | $-1.00 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 29, 2025 | After market close | $120.70M | $-0.95 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | After market close | $110.60M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 29, 2025 | After market close | $116.60M | $-0.88 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 20, 2025 | Before market open | $5.90M | $-1.40 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | $2.70M | $-0.86 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 1, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 2, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 22, 2024 | Before market open | – | – | – |
Press releases
Announcements BridgeBio Pharma filed with the SEC
BridgeBio Announces FDA Acceptance and Priority Review of NDA for
Other events · EX-99.1 to Form 8-K
BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
Other events · EX-99.1 to Form 8-K
BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder
Material agreement · Other events · EX-99.1 to Form 8-K
BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base
Material agreement · Other events · EX-99.2 to Form 8-K
BridgeBio Reports Second Quarter 2026
Results of operations · EX-99.1 to Form 8-K
BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1
Other events · EX-99.1 to Form 8-K
BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches
Material agreement · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
Other events · EX-99.1 to Form 8-K
BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
Other events · EX-99.1 to Form 8-K
BridgeBio Reports First Quarter 2026
Results of operations · Other events · EX-99.1 to Form 8-K
BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9
Other events · EX-99.1 to Form 8-K
BridgeBio Reports Fourth Quarter and
Results of operations · EX-99.1 to Form 8-K
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements
Other events · EX-99.1 to Form 8-K
BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.2 to Form 8-K
BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44 th Annual J.P. Morgan Healthcare Conference
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
J.P. Morgan Presentation January 12, 2026
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1
Other events · EX-99.1 to Form 8-K
BridgeBio Reports Third Quarter 2025
Results of operations · EX-99.1 to Form 8-K
BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in
Other events · EX-99.1 to Form 8-K
BridgeBio Reports Second Quarter 2025
Results of operations · EX-99.1 to Form 8-K
BridgeBio Reports First Quarter 2025
Results of operations · EX-99.1 to Form 8-K
PALO ALTO, Calif., March 17, 2025 (GLOBE
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt
Material agreement · Agreement terminated · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt
Material agreement · Agreement terminated · New financial obligation · Unregistered share sale · Other events · EX-99.2 to Form 8-K
BridgeBio Pharma Reports Fourth Quarter and
Results of operations · EX-99.1 to Form 8-K
BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
J.P. Morgan Presentation January 13, 2025
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)
Other events · EX-99.1 to Form 8-K
BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
BridgeBio Pharma Announces Proposed Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
BridgeBio Pharma Announces Pricing of Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
Forward-Looking Statement and Disclaimer The presentation may contain
Other events · EX-99.1 to Form 8-K
BridgeBio Pharma Reports Third Quarter 2023 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K